LAVA Therapeutics NV (LVTX)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch LVTX
See up to 3 months of LVTX. The 7-day demo opens the 1M and 3M ranges and puts LVTX on your watchlist.
Start 7-day demoLatest LVTX insider trades
About LAVA Therapeutics NV (LVTX)
The SEC lists LAVA Therapeutics NV under CIK 0001840748, in pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
LVTX Form 4 activity by transaction type, last 90 days
No Form 4 activity for LVTX in the last 90 days.
LVTX insider transactions (Form 4)
3014 Form 4 filings on record, the earliest from Sep 16, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Christy J. Oliger | Derivative | Share Options (Right to Buy) | 33,390 | $0.00 | - | |
| Mary E. Wadlinger | Derivative | Share Options (Right to Buy) | 33,390 | $0.00 | - | |
 Jay T. Backstrom | Derivative | Share Options (Right to Buy) | 33,390 | $0.00 | - | |
 Kapil Dhingra | Derivative | Common Shares | 30,000 | - footnote F1 | - | |
| Kapil Dhingra | Derivative | Share Options (Right to Buy) | 33,390 | $0.00 | - | |
| ||||||
| James Noble | Derivative | Share Options (Right to Buy) | 33,390 | $0.00 | - | |
| Fred M. Powell - Officer | Derivative | Common Shares | 65,000 | - footnote F1 | - | |
| Fred M. Powell - Officer | Derivative | Share Options (Right to Buy) | 124,700 | $0.00 | - | |
| ||||||
| Peter A. Kiener | Derivative | Share Options (Right to Buy) | 33,390 | $0.00 | - | |
| Karen J. Wilson | Derivative | Common Shares | 10,000 | - footnote F1 | - | |
| Karen J. Wilson | Derivative | Share Options (Right to Buy) | 33,390 | $0.00 | - | |
| ||||||
| Stephen A. Hurly - Officer | Derivative | Common Shares | 5,000 | - footnote F1 | - | |
| Stephen A. Hurly - Officer | Derivative | Share Options (Right to Buy) | 335,100 | $0.00 | - | |
| ||||||
| Gilde Healthcare Iv U.A. Cooperatieve | Open-market sale | Common Shares | 690,239 | $1.49 footnote F1 | $1.03M | |
| Gilde Healthcare Iv U.A. Cooperatieve | Open-market sale | Common Shares | 1,181,131 | $1.47 footnote F3 | $1.74M | |
| Gilde Healthcare Iv U.A. Cooperatieve | Open-market sale | Common Shares | 1,000,000 | $1.46 footnote F4 | $1.46M | |
| ||||||
| Gilde Healthcare Iv U.A. Cooperatieve | Open-market sale | Common Shares | 47,686 | $1.54 footnote F1 | $73K | |
| Gilde Healthcare Iv U.A. Cooperatieve | Open-market sale | Common Shares | 227,341 | $1.51 footnote F3 | $343K | |
| Gilde Healthcare Iv U.A. Cooperatieve | Open-market sale | Common Shares | 200,000 | $1.51 footnote F4 | $302K | |
| ||||||
| Gilde Healthcare Iv U.A. Cooperatieve | Open-market sale | Common Shares | 28,954 | $1.57 footnote F1 | $45K | |
| Gilde Healthcare Iv U.A. Cooperatieve | Open-market sale | Common Shares | 48,169 | $1.56 footnote F3 | $75K | |
| Gilde Healthcare Iv U.A. Cooperatieve | Open-market sale | Common Shares | 49,869 | $1.55 footnote F4 | $77K | |
| ||||||
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 2,370,533 | $1.40 | $3.32M | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 532,870 | $1.40 | $747K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 307,707 | $1.53 | $472K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 192,293 | $1.53 | $295K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 362,806 | $1.49 | $540K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 226,726 | $1.49 | $338K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 366,111 | $1.44 | $528K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 228,791 | $1.44 | $330K | |
LVTX insider trading FAQ
What is the latest insider trade for LVTX?
LAVA Therapeutics NV (LVTX) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-11-17. The full record for LVTX runs to 14 Form 4 filings, the earliest from 2025-09-16. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying LVTX stock?
No insider purchases of LVTX were filed in the last 90 days.
How many insiders are selling LVTX stock?
No insider sales of LVTX were filed in the last 90 days. 17 sales are on record for this company.
Where can I see LVTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects LVTX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Christy J. Oliger view on EDGAR
- - Mary E. Wadlinger view on EDGAR
- - Jay T. Backstrom view on EDGAR
- - Kapil Dhingra view on EDGAR
- - James Noble view on EDGAR
- - Fred M. Powell view on EDGAR
- - Peter A. Kiener view on EDGAR
- - Karen J. Wilson view on EDGAR
- - Stephen A. Hurly view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where LVTX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow LVTX with a 7-day demo
- LVTX on your watchlist
- Every LVTX Form 4 filing on record
- Up to 3 months of LVTX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
